The Cost Of Coronavirus: Medtech Market Wins And Losses
With the rapid global spread of the coronavirus, Medtech Insight looks at the predicted economic impact of the outbreak on the industry’s biggest businesses.
You may also be interested in...
Medtronic's revenue for the fourth quarter of fiscal 2020 was down 25% year-year-over due to the COVID-19 pandemic. The hardest-hit segment was restorative therapies, which reported a 33% year-over-year decline in the quarter due to the drop off in deferrable procedures and capital purchases. For the full fiscal year, Medtronic's revenue was down 4.2% to $28.9bn.
As the pandemic unfolds with an uncertain outcome, US securities analysts that cover publicly traded medtech companies are developing mathematical models to estimate the impact of the COVID-19 pandemic on medtech companies.